Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, knockout of B-raf and C-raf genes in mice showed they are not needed for early melanocyte development, but are crucial for maintaining melanocyte stem cells, as evidenced by hair graying due to stem cell depletion.

In preclinical studies, a B-Raf inhibitor called WYE-130600 caused dose-related skin effects in dogs and rats, suggesting potential similar responses might occur in humans.

Male hair loss is mainly due to thinner hair, not less hair.

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

This study found that β-sitosterol, a brain-penetrable phytosterol, reduced melanoma cell growth and brain metastasis formation by interfering with mitochondrial respiration, suggesting its potential as an adjuvant therapy to BRAF inhibitors for patients with melanoma brain metastases.

This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.

This study found that topical application of the BRAF inhibitor vemurafenib improved wound healing and promoted hair follicle regeneration in a diabetic murine model.

Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.

This letter to the editor shares a case study of lentiginous melanoma that appears clinically malignant but histopathologically benign, involving the BRAFV600R mutation.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review discusses melanocyte biology and its genetic and molecular basis, highlighting its relevance in understanding diseases like vitiligo and albinism, and reports no new findings.

This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.

In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.

This review discusses the various skin, mucosa, and adnexa side effects associated with different chemotherapeutic agents and provides insights into their clinical presentation and management; it reports no new results.

This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This article provides a narrative on managing dermatologic side effects from cancer therapies and suggests strategies that oncologists could adopt, but it reports no new clinical findings.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

This study explored the immune environment of the hair follicle's bulge region and suggested that its unique signaling may prevent melanoma formation by lacking necessary proinflammatory signals for full oncogenic transformation, indicating potential strategies for melanoma prevention by replicating this immune-privileged environment.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This review discusses the epidemiology, risk factors, clinical features, and management of scalp melanomas, highlighting their high mortality rates and specific challenges in diagnosis and treatment; it reports no new research findings.

This case report describes a 33-year-old woman with long-standing scalp issues and hair loss, revealing an unusual connection to past melanoma, but it presents no new research results.